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Abstract 
Purpose: To present an overview of the ethnobotany, phytochemistry and pharmacology of Crinum 
bulbispermum so as to understand its importance and potential in primary healthcare systems. 
Methods: A review of the literature was undertaken and an in-depth analysis of previous research on 
ethnobotany, phytochemistry and pharmacology of C. bulbispermum. Literature sources included 
papers published in journals, reports from international, regional and national organizations, conference 
papers, books and theses. Electronic search engines such as Google, Google scholar, publishing sites 
such as Elsevier, scienceDirect, BioMed Central (BMC), PubMed and other scientific database sites 
such as ChemSpider, PubChem were used. 
Results: Crinum bulbispermum is a popular medicinal plant in southern Africa used as remedy for 
aching joints, rheumatism, kidney or bladder infections, septic sores and wounds. The chemical 
composition of C. bulbispermum is dominated by various alkaloids and non-alkaloids isolated from the 
bulbs, flowers, flowering stalks, leaves and roots. Major biological activities demonstrated by C. 
bulbispermum include antimicrobial, antioxidant, actinociceptive, antiplasmodial activities as well as 
effects on the central nervous system.  
Conclusion: The widespread usage of C. bulbispermum as herbal medicine is threatening wild 
populations, and this calls for conservation strategies and mechanisms for sustainable utilization of the 
species.  
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Crinum bulbispermum (Burm. f.) Milne-Redh. & 
Schweick. is a deciduous bulbous plant which 
belongs to the Amaryllidaceae family. Crinum 
bulbispermum was initially described as 
Amaryllis bulbispermum Burm. f. and then 
mistakenly identified as Amaryllis longifolia L. 
which is now Cybistetes longifolia (L.) Milne-
Redh. & Schweick. [1-3]. However, Milne-
Redhead and Schweickerdt [2] simplified the 
matter in their revision of the genus Ammocharis 
by suggesting the new combination, C. 
bulbispermum, based on A. bulbispermum Burm. 
[3]. Crinum bulbispermum is a perennial herb 
growing to about 1 m tall, with a very large bulb, 
10-11 cm in diameter covered with bases of older 
leaves and vermiform roots at the base [4]. 
Crinum bulbispermum has many, thick, stout, 
simple and glaucous green leaves, measuring 
78-92 cm long, 6-6.7 cm broad, oblong to linear 
in shape, acuminate, flat and shining, margin 
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slightly scabrous and undulate [3]. The peduncle 
is 50-90 cm long and has an umbel with between 
6 to 16 flowers, which are white in colour with a 
dark red keel or entirely suffused with red; the 
stamens are declinate, white or suffused with 
pink and the style deep pink in the upper portion 
with a light brown stigma [4]. Crinum 
bulbispermum occurs naturally along rivers and 
streams or in damp depressions in black clay or 
sandy soils in Lesotho, South Africa and 
Swaziland [4].  
 
The plant is cultivated throughout the world for its 
beautiful and trumpet or bell-shaped flowers. Like 
most medicinal plants in Southern Africa, C. 
bulbispermum is collected from the wild. The 
unsustainable harvesting of C. bulbispermum as 
herbal medicine and ornamental plant is 
threatening its continued existence. Although C. 
bulbispermum is widespread in South Africa, its 
population is declining due to over-exploitation of 
its bulbs which are sold in the medicinal (muthi) 
markets in Durban [5,6], Johannesburg [6,7] and 
Polokwane [8] in South Africa. Raimondo et al [9] 
categorized C. bulbispermum as declining in 
South Africa based on the modified IUCN Red 
List Categories and Criteria version 3.1 of 
threatened species [10-12]. According to Victor 
and Keith [11] and von Staden et al [12], a 
species listed as Least Concern (LC) under the 
IUCN Red List Categories and Criteria version 
3.1 [10] can additionally be categorized either as 
rare, critically rare or declining. The observed 
population decline of C. bulbispermum in South 
Africa [9] is due to over-exploitation as an 
ornamental plant, medicinal plant trade and 
popularity of the species in the medicinal plant 
(muthi) markets. It is within this context that the 
current study was carried out, aimed at 
comprehensively documenting the ethnobotany, 
phytochemistry and pharmacology of C. 
bulbispermum so as to highlight research gaps 
and provide a foundation for further 
investigations on the plant species. 
 
Traditional medicinal usage 
 
Crinum bulbispermum is a popular medicinal 
plant in both rural and urban communities in 
Southern Africa [6,7,13,14]. It is commonly 
known as Orange river lily in English in South 
Africa and it is also known by various vernacular 
and synonym names in different geographical 
regions in Lesotho, South Africa and Swaziland 
(see Table 1). In South Africa, the roasted bulbs 
of C. bulbispermum are applied to aching joints, 
rheumatism, varicose veins and backache, 
kidney or bladder infections and are used as 
poultices for septic sores and abscesses [13]. 
The southern Sotho in South Africa use the 
leaves and sliced or crushed bulbs to make a 
strong brew for treating colds, coughs, and as an 
external application or wash for wounds, scrofula 
and haemorrhoids (Table 2). According to 
Roberts [13], the leaves are used to bind 
dressings in place and flowers are placed over 
swollen joints and sprains to reduce swelling. 
Unspecified parts are used as infusions during 
pregnancy to ensure easy delivery [15]. The 
bulbs of C. bulbispermum are used for colds and 
to stimulate breast milk supplies by the Sotho in 
Lesotho [16]. Several tribes in Lesotho, South 
Africa and Swaziland are reported to use the 
juice squeezed from the base of the leaves to 
cure earache [13,17]. Sometimes pieces of 
roasted bulb are placed behind the ear or over 
the ear to ease the pain. Roberts [13] reports that 
some tribes in South Africa make a brew of the 
leaves which they believe to be an effective 
treatment for malaria. This same brew is drunk 
by the Zulu in South Africa as a treatment for 
rheumatic fever (usually half a cup chopped 
leaves in one cup boiling water and strained after 
standing for five minutes). The Tswana in South 
Africa drink a brew of crushed leaf bases and 
stalks to increase the flow of urine in bladder and 
kidney infections. The sliced bulb is also warmed 
and applied over the kidneys to ease discomfort 
[13]. Hutchings [18] records the use of C. 
bulbispermum bulb as a Zulu, Xhosa and Sotho 
gynaecological remedy and charm. Crinum 
bulbispermum leaves are browsed by cattle in 




Various reports on the phytochemical screening 
of C. bulbispermum bulbs, flowers, flowering 
stalks, leaves and roots confirm the presence of 
isoquinoline alkaloids, flavonoids, sterols, 
aldehydes, acids, esters, alcohols, esters, 
amines and amides, fatty acids and their esters 
(Table 3). Alkaloids are considered the major 
bioactive components of C. bulbispermum which 
exhibits various pharmacological effects 
[24,32,36-41]. Six distinct and structurally diverse 
isoquinoline alkaloids characteristic of the 
Amaryllidaceae family [42] have been isolated 
from C. bulbispermum, namely lycorine-type 
alkaloid (represented by eight alkaloids, alkaloids 
1-8); galanthamine-type alkaloid represented by 
galanthamine 9; cherylline-type alkaloid 
represented by cherylline 10; crinine-type 
alkaloid (represented by 29 alkaloids, alkaloids 
11-39), tazettine-type alkaloid (represented by 
8α-ethoxyprecriwelline39, N-desmethyl-8α-
ethoxypretazettine 40 and N-desmethyl-8β-
ethoxypretazettine 41) and two minor alkaloids 
namely augustamine 42 and trisphaeridine 43 
(Table 3). Non-alkaloid compounds isolated from 
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C. bulbispermum bulbs, flowers and leaves are 
flavonoids represented by 15 compounds 
(compounds 44-58); sterols represented by 
dihydrositosterol 59 and stigmasterol 60; 
aldehydes, acids and esters represented by 4,5-
methylenedioxy-4'-hydroxy-2-aldehyde-(1,1'-
biphenyl) 61 and ρ-hydroxybenzene acetic acid 
ethyl ester 62; alcohols, esters, amines and 
amides represented by β-(3,4-dimethoxyphenyl)-
α,β-ethanediol 63 and choline 64; and fatty acids 
and their esters represented by nine compounds, 
compounds 65-73 (see Table 3). Although very 
little pharmacological evaluation of non-alkaloid 
compounds isolated from C. bulbispermum has 
been done to date, flavonoids are known to 
exhibit antioxidant activity, free radical 
scavenging capacity, coronary heart disease 
prevention, hepatoprotective, anti-inflammatory, 
anticancer and antiviral activities [43]. While 
phytosterols are known to have bioactive 
prevention properties such as lowering of 
cholesterol levels [44] and cancer prevention [45] 
properties. Previous research by Li et al [46] 
showed that unsaturated fatty acids have 





A number of pharmacological activities of C. 
bulbispermum have been reported in literature 
justifying some of its ethnomedicinal uses. Some 
of the listed pharmacological activities may not 
relate directly to the ethnomedicinal uses of C. 
bulbispermum, but may provide some insight into 
its potential therapeutic value and bioactive 
properties. A wide range of biological activities 
have been reported including antimicrobial [36], 
antinociceptive [37], antiplasmodial [38], 
antioxidant [37,39], cytotoxicity and anti-apoptotic 
[24,37,40,41] as well as effects on the central 
nervous system (CNS) [37]. 
 
Effects on the central nervous system (NCS) 
 
In recent years, members of the Amaryllidaceae 
family have been shown to contain alkaloids with 
promising acetylcholinesterace (AChE) inhibiting 
properties [47,48]. Adewusi and Steenkamp [39] 
found ethyl acetate extracts of C. bulbispermum 
bulbs and roots as well as methanol bulb extract 
to have some level of inhibitory activity against 
AChE with IC50 values of 0.0021 ± 0.007, 0.0393 
± 0.014 and 0.0148 ± 0.039 mg/mL, respectively. 
 
Table 1: Vernacular names and synonyms of Crinum bulbispermum 
 
Vernacular name(s) with ethnic group/geographical region in brackets Country Reference 
Lelutla, mototse (Sesotho) Lesotho [20] 
Orange rivierle lie, Vaalrivierle lie, Vleilelie (Afrikaans), Orange river lily, wild 
amaryllis (English), lelutla, mototse (Sotho), mduze, umduze, umduzi, 
umnduze (Zulu) 
South Africa [5,6,8,14] 
Umnduze (Swazi) Swaziland [19] 
Synonym   
Amaryllis bulbispermum Burm. f.  [4] 
Amaryllis longifoliasensu Jacq.  [4] 
Amaryllis longifolia var. riparia Ker-Gawl.  [4] 
Crinum capense sensu Herb.  [4] 
Crinum longifolium (L.) Thunb.  [4] 
Crinum riparium Herb.  [4] 
 
Table 2: Ethnomedicinal uses of Crinum bulbispermum in Southern Africa 
 
Use Country practised References 
Abscesses and sores South Africa [17] 
Aching joints South Africa [13] 
Backache South Africa [17] 
Binding for dressings South Africa [17] 
Charm Lesotho; South Africa [16,18] 
Colds Lesotho; South Africa [13] 
Coughs Lesotho; South Africa [13] 
Earache South Africa [17] 
Gynaecological remedy South Africa [18] 
Haemorrhoids South Africa [13,17] 
Kidney and bladder infections (increase urine flow) South Africa [17] 
Malaria South Africa [17] 
Reduce swelling of swollen joints and sprains South Africa [17] 
Scrofula South Africa [13] 
Varicosities South Africa [17] 
Wounds South Africa [13] 
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 Table 3: Alkaloids and non-alkaloids isolated and characterized from Crinum bulbispermum 
 
S/No. Alkaloid Plant part References 
 Lycorine-type alkaloid   
1 Lycorine Bulbs, flowering stalks, roots  [21,22] 
2 1, 2-di-O-acetyllycorine Bulbs [23] 
3 8-hydroxylycorine-7-one Bulbs [24] 
4 Hippacine Bulbs [25] 
5 Hippadine (pratorine) Bulbs [21] 
6 Hippamine Bulbs [24] 
7 Pratorinine Bulbs [26,27] 
8 Protorimine Bulbs [28] 
 Galanthamine-type alkaloid   
9 Galanthamine Bulbs [26,27] 
 Cherylline-type alkaloid   
10 Cherylline Bulbs [23] 
 Crinine-type alkaloid   
11 Crinine Bulbs [22,23] 
11 3-O-Acetyl-crinine (krepowine) Bulbs [23,28] 
12 3-O-acetylhamayne Bulbs, flowering stalks, roots [29,30] 
13 3-O-acetyl-powelline Bulbs [28] 
14 3,4-anhydropowelline Bulbs [28] 
15 6-hydroxycrinamine Bulbs, flowering stalks, roots [30] 
16 11-hydroxyvittatine Bulbs [24] 
17 Bowdensine Bulbs [23] 
18 Bulbisine Bulbs [28] 
19 Bulbispermine Bulbs, flowering stalks, roots [29,31] 
20 buphanamine Bulbs [26,27] 
21 Buphanidrine-6-β-ethoxy Bulbs [28] 
22 Buphanisine Bulbs [28] 
23 Buphanisine-6-α-hydroxy Bulbs [28,32] 
24 Buphanisine-6-β-hydroxy Bulbs [28] 
25 Buphanisine-6-α-ethoxy Bulbs [28] 
26 Crinalbine Bulbs [21] 
27 Crinamidine Bulbs [23] 
28 Crinamine Bulbs, flowering stalks, roots [21-23,30]  
29 Crinamine-6-α-hydroxy Bulbs, flowering stalks, roots [22,29] 
30 Crinamine-6-β-hydroxy Bulbs, flowering stalks, roots [22,29] 
31 Crinine-6-α-hydroxy Bulbs [28] 
32 Crinine-6-β-hydroxy Bulbs [28] 
33 Crinine-6-α-ethoxy Bulbs [28] 
34 deacetylbowdensine Bulbs [23] 
35 Hamayne Bulbs [21,31] 
36 Powelline Bulbs [22,23] 
37 Powelline-6-α-ethoxy Bulbs [28] 
38 Vittatine Bulbs [26,27] 
 Tazettine type alkaloid   
39 8α-ethoxyprecriwelline Bulbs, flowering stalks, roots [29] 
40 N-desmethyl-8α-ethoxypretazettine Bulbs, flowering stalks, roots [29] 
41 N-desmethyl-8β-ethoxypretazettine Bulbs, flowering stalks, roots [29] 
 Other minor alkaloids   
42 Augustamine Bulbs [28,32] 
43 Trisphaeridine Bulbs [28] 
  
Non alkaloid compounds 
  
 Flavonoids   
44 4'-hydroxy-7-methoxy-flavan Bulbs [28] 
45 2(S)3',4'-dihydroxy-7-methoxy-flavan Bulbs [25] 
46 4'-dihydroxy-7-methoxy-flavan-3-ol Bulbs [25] 
47 7,4'-dihydroxy-flavanone[(-)-liquiritigenin] Bulbs [25] 
48 7'-hydroxy-8-methoxy-flavanone[lsolarrien] Bulbs [25] 
49 4'-hydroxy-7-methoxy-flavone Bulbs [33] 
50 4,4'-dihydroxy-2-methoxy-chalcone Bulbs [33] 
51 2',4,4'-trihydroxy-chalcone(Isoliquiritigenin) Bulbs [25] 
52 4-hydroxy-2',4'-dimethoxy-dihydrochalcone Bulbs [25] 
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Table 3: Alkaloids and non-alkaloids isolated and characterized from Crinum bulbispermum (Continued) 
 





54 Kaempferol-3-O-glucoside Flowers [34] 








 Sterols   
59 Dihydrositosterol Bulbs, leaves [35] 
60 Stigmasterol Bulbs, leaves [35] 
 Aldehydes, acids and esters   
61 4,5-methylenedioxy-4'-hydroxy-2-aldehyde-(1,1'-biphenyl) Bulbs [25] 
62 ρ-hydroxybenzene acetic acid ethyl ester Bulbs [33] 
 Alcohols, esters, amines and amides   
63 β-(3,4-dimethoxyphenyl)-α,β-ethanediol Bulbs [33] 
64 Choline Bulbs [21] 
 Fatty acids and their esters   
65 Linoleic acid Bulbs [35] 
66 Linoleic acid methyl ester Bulbs, leaves [35] 
67 Oleic acid Bulbs, leaves [35] 
68 Palmitic acid Bulbs, leaves [35] 
69 Palmitic acid methyl ester Bulbs, leaves [35] 
70 n-Hexacosane Bulbs, leaves [35] 
71 n-Heptacosane Bulbs, leaves [35] 
72 n-Nonacosane Bulbs, leaves [35] 
73 n-Pentacosane Bulbs, leaves [35] 
 
In an earlier research, orally administered 
aqueous leaf extract of C. bulbispermum doses 
of 1, 1.5 and 3 g/kg showed central inhibitory 
activity and markedly impaired the four 
parameters of rat hold-board test indicating its 
sedative properties [37]. The ability of C. 
bulbispermum to inhibit acetylcholinesterase may 
be ascribed to several alkaloids which have been 
isolated from the plant species (Table 3) 
indicating its potential for use in treatment of 
neurodegenerative diseases. Recently, the 
alkaloid galanthamine 9 isolated from C. 
bulbispermum (Table 3) was approved in the 
United States, many European countries and 
many Asian countries for the treatment of 
Alzheimer’s disease (AD) [49]. Alzheimer’s 
disease is characterized by a progressive 
impairment of cognitive functions including loss 
of memory and the inability to perform basic daily 
life activities [48]. Based on the cholinergic 
hypothesis, these symptoms are the results of 
the reduction in brain acetylcholine activity due to 
the catabolism of acetylcholine by ACHE [48]. 
Other alkaloids isolated from C. bulbispermum 
which have been screened for AChE inhibition 
activity include crinine 11 which exhibited 
inhibitory activity with IC50 of 461 μM, crinamine 





A methanol bulb extract of C. bulbispermum 
showed some radical scavenging activity in 
ABTS assays with IC50 value of 0.0685 ± 0.041 
mg/mL [39]. The total phenolic, flavonol and 
flavonoid contents of C. bulbispermum roots 
were relatively high for both solvents tested with 
total phenol of 202.38 ± 0.50 mg tannic acid/g, 
flavonol (20.79 ± 0.10 mg quercetin/g) and 
flavonoid (9.18 ± 0.50 mg quercetin/g) [39]. The 
levels of these phenolic compounds are an 
indication of the potential antioxidant activity of 
the plant extracts as phenolic compounds are 
well known as radical scavengers, metal 
chelators, reducing agents, hydrogen donors and 
singlet oxygen quenchers [50,51]. Additionally, 
the leaf extracts of C. bulbispermum showed 
modest antioxidant activity with EC50 value of 
203.76 µg/mL which was assessed by the 
thiobarbituric acid reactive substances assay 
[37]. These findings support the traditional use of 
the plant species for treating neurological 
disorders especially those involving 
cholinesterase mechanism and reactive oxygen 
species.  
 
Antinociceptive activity  
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Ratnasooriya et al. [37] evaluated the 
antinociceptive activity of C. bulbispermum 
leaves using three models of nociception namely 
tail flick, hot plate and formalin tests in male rats. 
The results showed that the leaf extracts had 
marked antinociceptive potential, particularly, 
when evaluated in the formalin test. According to 
Ratnasooriya et al [37], the obtained results 
suggest that the antinociception is mediated both 
spinally and supraspinally and is effective against 
phasic and continuous non-inflammatory or 
inflammatory pain. Ratnasooriya et al [37] 
attributed the antinociception of the leaf extract of 
C. bulbispermum to the results of opioid 
mechanisms, sedation and antioxidant activities 
of the species. These results support the 
traditional use of the species in various 
inflammatory ailments and diseases ranging from 
microbial infection to injury that result in swelling, 




Van Dyk et al [38] screened C. bulbispermum for 
antiplasmodial activity using the [3H]-
hypoxanthine incorporation assay against the 
chloroquine-resistant Plasmodium falciparum. 
Extracts of C. bulbispermum had IC50 values ≤ 1 
µg/mL with the ethyl acetate extracts of the roots 
and bulbs having values comparable to 
chloroquine (0.04 µg/mL). Van Dyk et al [38] 
identified lycorine 1 as a potent antiplasmodial 
compound with an IC50 value of 0.03 µg/mL 
against the chloroquine-resistant strain (FCR-3) 
of P. falciparum, which is comparable to the 
activity of the crude extract and chloroquine. The 
most promising extract was the ethyl acetate 
bulb extract of C. bulbispermum with an IC50 
value of 0.08 µg/mL and a security index of 
2203.13. Likhitwitaywuid et al [52] reported an 
IC50 value of 0.3 μg/mL for lycorine 1 isolated 
from C. amabile against the chloroquine-resistant 




Griffiths [36] assessed antimicrobial activity of C. 
bulbispermum using the direct plate method and 
minimum inhibitory concentration values were 
determined. The best activity was observed for 
the alkaloid lycorine 1 against Bacillussubtilis 
[36]. One of the most common ethnomedicinal 
uses of C. bulbispermum is in the treatment of a 
wide range of infectious diseases caused by 
microorganisms such diseases or ailments 
include symptoms such as sores [17] and 
wounds [13]. Previous research showed that 
some of the alkaloids that have been isolated 
from C. bulbispermum have antibacterial activity. 
For example, the alkaloid crinamine 28 is known 
to have antibacterial activity, as it showed some 
strong activity against Bacillus subtilis and 
Staphylococcus aureus [53]. 
 
Cytotoxicity and anti-apoptotic activity 
 
Seoposengwe et al [41] evaluated the 
cytoprotective potential of C. bulbispermum, after 
induction of toxicity using rotenone, in SH-SY5Y 
neuroblastoma cells. Rotenone reduced 
intracellular reactive oxygen species (ROS) 
levels after 24 h exposure. Pre-treating cells with 
C. bulbispermum extracts reversed the effects of 
rotenone on intracellular ROS levels. Rotenone 
exposure also decreased intracellular glutathione 
levels, which was counteracted by pre-treatment 
with any one of the extracts. MMP was reduced 
by rotenone, which was neutralized by pre-
treatment with C. bulbispermum ethyl acetate 
extract. All extracts inhibited rotenone-induced 
activation of caspase-3. Crinum bulbispermum 
demonstrated anti-apoptotic activity and restored 
intracellular glutathione content following 
rotenone treatment, suggesting that they may 
possess neuroprotective properties. 
 
Ratnasooriya et al [37] evaluated the sub-chronic 
toxicity of the aqueous leaf extract of C. 
bulbispermum. The extract induced mild to 
moderate toxicity in rats which developed 
diarrhoea and postural abnormalities on the 
second day, and two rats died by the fourth day. 
Liver and renal toxicities (increase of serum 
SGOT, SGPT, creatinine and urea) were also 
reported and the authors attributed this toxicity to 
the lycorine- and crinine-types of alkaloids 
present in C. bulbispermum (see Table 3). 
According to van Wyk et al [54] the major toxic 
compound in C. bulbispermum is the alkaloid 
crinamine 28, which is regarded as highly lethal 
with an oral lethal dose LD50 at a concentration of 
10 mg/kg body weight in dogs. Crinamine 28 is 
regarded as a powerful transient hypotensive in 
dogs and also shows respiratory depressant 
activity [55]. Similarly, Aboul-Ela et al [24] tested 
cytotoxicity of C. bulbispermum bulbs using the 
brine shrimp bioassay. The most effective one 
were the butanol fraction of the acidic extract of 
the non-flowering bulbs with LD50 of 63.1 μg/mL 
followed by the ether fraction of the alkaline 
extract of the flowering bulbs with LD50 of 73 
μg/mL.  
 
Van Dyk et al [38] evaluated the cytotoxicity of C. 
bulbispermum compounds as determined by in 
vitro cellular toxicity assay, reporting the IC50 
value of 445.47 μg/mL for lycorine 1 against 
human kidney epithelial cells and toxicity index of 
> 15 000. Other researchers like Campbell et al 
[56] evaluated cytotoxicity activities of alkaloids 
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associated with C. bulbispermum reporting IC50 
values of 0.6 and 0.7 μg/mL for lycorine 1 
against the strains D-10 and FAC8, respectively. 
Likhitwitaywuid et al [52] reported IC50 values for 
ranging from 0.3 to 1.6 μg/mL against a series of 
human cancer cells. The anti-cancer activity of 
lycorine 1 was also reported by Li et al [57] as an 
effect due to the apoptosis inducing effect of 
lycorine 1 and it has been found to inhibit protein 
synthesis. Abd El Hafiz et al [32] examined the 
constituents of C. bulbispermum for activity 
against human leukemic Molt 4 cells. Of the 
flavan, 4'-hydroxy-7-methoxyflavan 44 and three 
crinanes namely powelline 36, crinine-6-α-
hydroxy 31 and buphanisine-6-α-hydroxy 23 
tested, only buphanisine-6-α-hydroxy 23 and 4'-
hydroxy-7-methoxyflavan 44 were moderately 
active, causing a steady decline (up to about 20 
%) in the viability of leukemia cells over the 
three-day treatment period at a dosage of 71 
µg/mL.  
 
Seoposengwe et al [41] found the ethyl acetate 
extract of C. bulbispermum to have the least 
cytotoxic with an LC50 value of > 100 μg/mL. 
Contrary to this, the methanol extract produced 
an LC50 value of 46.18 ± 0.91 μg/mL. Adewusi et 
al [40] evaluated cytotoxicity of C. bulbispermum 
ethanol extracts against SH-SY5Y (human 
neuroblastoma) cells as well as toxically induced 
with Aβ, using the MTT and neutral red uptake 
assays. The extracts of the root and bulb of C. 
bulbispermum were the most toxic with IC50 
values < 50 μg/mL in both assays. However, 
despite the observed toxicity, the roots and bulbs 
of C. bulbispermum still reduced the cell death 
induced by Aβ at less toxic doses. These results 
show that C. bulbispermum may contain several 




The widespread usage of C. bulbispermum as an 
ornamental plant and in traditional medicine 
resulting in negative impact on wild populations 
calls for conservation strategies and mechanisms 
for sustainable utilization of the species. The 
estimated declining rate of C. bulbispermum [9] 
is based on the decreasing population numbers 
at known habitat sites and reduction in the bulb 
sizes of the species sold in medicinal muthi 
markets [7]. Therefore, propagation protocols for 
C. bulbispermum should be developed as an 
alternative and viable means to provide sufficient 
plants to meet the demand for ornamental and 
medicinal purposes and at the same time 
protecting the natural populations. There is also 
need for comparative evaluation of the 
phytochemistry and biological activities of the 
various plant parts in an attempt to suggest plant 
part substitution as a means of conserving this 
highly collected plant species. If phytochemical 
and biological analyses prove that the leaves, 
flower stalks, flowers and fruits have comparable 
properties and activities to those of the bulbs and 
roots, then plant part substitution can be used to 
curtail the destructive harvesting of bulbs that 
has led to a continuous decimation of the wild 
populations. 
 
The present review summarizes ethnomedicinal 
uses, phytochemistry, biological activities and 
cytotoxicity of different extracts and compounds 
of C. bulbispermum. Crinum bulbispermum has 
been traditionally used as herbal medicine 
throughout its distributional range in southern 
Africa, used for the treatment of common 
diseases and ailments like colds, cough, 
earache, haemorrhoids, malaria, wounds and 
others medical complications like gynaecological, 
kidney and bladder problems. Recent research 
on C. bulbispermum focused primarily on 
evaluating the antimicrobial, antioxidant, 
antiplasimodial, cytotoxicity activities of the 
species as well as the effects on the central 
nervous system. Alkaloids appear to be the 
major ingredients in C. bulbispermum bulbs, 
flowers, flower stalks, leaves and roots and these 
compounds appear to be responsible for the 
pharmacological properties of the species. Other 
important phytochemical constituents isolated 
from C. bulbispermum bulbs, flowers and leaves 
are flavonoids, sterols, aldehydes, acids and 
esters, alcohols, esters, amines, amides and 
fatty acids and their esters. Surprisingly, there is 
no systematic data linking the ethnomedicinal 
uses of C. bulbispermum to the phytochemical 
and pharmacological properties of these non-
alkaloid compounds. Future studies should 
therefore, try to establish a link between the 
phytochemical and pharmacological properties of 
the non-alkaloid compounds and the 
ethnomedicinal uses of C. bulbispermum. 
 
Although contemporary research involving C. 
bulbispermum is promising, it is too preliminary 
and sometimes too general to be used to explain 
and support its ethnomedicinal uses. Most of the 
mentioned phytochemical constituents and 
pharmacological studies have provided some 
suggestive scientific evidence for the various 
ethnomedicinal uses of C. bulbispermum in the 
treatment of parasitic diseases such as control 
and management of malaria, inflammatory 
ailments and wounds; there is need for extensive 
phytochemical, pharmacological, preclinical and 
clinical research. There is yet not enough 
Maroyi 
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systematic data regarding the pharmacokinetics 
and clinical research of C. bulbispermum 
products and compounds. There are very few to 
nil experimental animal studies, randomized 
clinical trials and target-organ toxicity studies 
involving C. bulbispermum and its derivatives 
that have been carried out so far. Therefore, 
studies should identify the bioactive components, 
details of the molecular modes or mechanisms of 
action, pharmacokinetics and physiological 
pathways for specific bioactives of C. 
bulbispermum. Future studies should include the 
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